Intrahepatic cholangiocarcinoma in a transplant liver - selective internal radiation therapy followed by right hemihepatectomy: report of a case

World Journal of Surgical Oncology

Otto Kollmar²  Roland Seidel¹  Christian Ziemann²  Jochen Schuld²  Christoph Justinger²  Jens Sperling² 

[1] Department of Diagnostic and Interventional Radiology, University of Saarland, D-66421 Homburg-Saar, Germany;Department of General, Visceral, Vascular and Pediatric Surgery, University of Saarland, D-66421 Homburg-Saar, Germany

关键词: Selective internal radiation therapy;    Intrahepatic cholangiocarcinoma;    Liver resection;    Liver transplantation;   

Others  :  1148832
DOI  :  10.1186/1477-7819-12-198

 received in 2014-02-18, accepted in 2014-06-12,  发布年份 2014

【 摘 要 】

Intra- or extrahepatic cholangiocarcinomas are the second most common primary liver malignancies behind hepatocellular carcinoma. Whereas the incidence for intrahepatic cholangiocarcinoma is rising, the occurrence of extrahepatic cholangiocarcinoma is trending downwards. The treatment of choice for intrahepatic cholangiocarcinoma remains liver resection. However, a case of liver resection after selective internal radiation therapy in order to treat a recurrent intrahepatic cholangiocarcinoma in a transplant liver is unknown in the literature so far. Herein, we present a case of a patient undergoing liver transplantation for Wilson’s disease with an accidental finding of an intrahepatic cholangiocarcinoma within the explanted liver. Due to a recurrent intrahepatic cholangiocarcinoma after liver transplantation, a selective internal radiation therapy with yttrium-90 microspheres was performed followed by right hemihepatectomy. Four years later, the patient is tumor-free and in a healthy condition.

【 授权许可】

   
2014 Sperling et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Park J, Kim MH, Kim KP, Park do H, Moon SH, Song TJ, Eum J, Lee SS, Seo DW, Lee SK: Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 2009, 3:298-305.
• [2]Kim YI, Park JW, Kim BH, Woo SM, Kim TH, Koh YH, Lee WJ, Kim CM: Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma. Radiat Oncol 2013, 21(8):292-298.
• [3]Rana A, Hong JC: Orthotopic liver transplantation in combination with neoadjuvant therapy: a new paradigm in the treatment of unresectable intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol 2012, 28(3):258-265.
• [4]Pracht M, Le Roux G, Sulpice L, Mesbah H, Manfredi S, Audrain O, Boudjema K, Raoul JL, Boucher E: Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years. Chemotherapy 2012, 58(2):134-141.
• [5]Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM, Gores GJ: Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 2014. epub ahead of print
• [6]Ibrahim SM, Mulcahy MF, Lewandowski RJ, Sato KT, Ryu RK, Masterson EJ, Newman SB, Benson A, Omary RA, Salem R: Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer 2008, 113(8):2119-2128.
• [7]Saxena A, Bester L, Chua TC, Chu FC, Morris DL: Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol 2010, 17(2):484-491.
• [8]Wijlemans JW, Van Erpecum KJ, Lam MG, Seinstra BA, Smits ML, Zonnenberg BA, Van Den Bosch MA: Trans-arterial (90) yttrium radioembolization for patients with unresectable tumors originating from the biliary tree. Ann Hepatol 2011, 10(3):349-354.
• [9]Rafi S, Piduru SM, El-Rayes B, Kauh JS, Kooby DA, Sarmiento JM, Kim HS: Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol 2013, 36(2):440-448.
• [10]Sulpice L, Rayar M, Boucher E, Pracht M, Meunier B, Boudjema K: Treatment of recurrent intrahepatic cholangiocarcinoma. Br J Surg 2012, 99(12):1711-1717.
• [11]Hyder O, Marsh JW, Salem R, Petre EN, Kalva S, Liapi E, Cosgrove D, Neal D, Kamel I, Zhu AX, Sofocleous CT, Geschwind JF, Pawlik TM: Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol 2013, 20(12):3779-3786.
• [12]Bruix J, Sherman M, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: an update. Hepatology 2011, 53(3):1020-1022.
• [13]Petrowsky H, Hong JC: Current surgical management of hilar and intrahepatic cholangiocarcinoma: the role of resection and orthotopic liver transplantation. Transplant Proc 2009, 41(10):4023-4035.
• [14]Aljiffry M, Walsh MJ, Molinari M: Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990 to 2009. World J Gastroenterol 2009, 15(34):4240-4262.
• [15]Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD: Cholangiocarcinoma. Lancet 2005, 366(9493):1303-1314.
• [16]Farges O, Fuks D: Clinical presentation and management of intrahepatic cholangiocarcinoma. Gastroenterol Clin Biol 2010, 34(3):191-199.
• [17]Farinati F, Giacomin A, Vanin V, Sergio A, Burra P, Cillo U, Di Nolfo A, Del Poggio P, Benvegnu L, Zoli M, Borzio F, Giannini EG, Caturelli E, Cazzagon N, Rapaccini GL, Trevisani F, Italian Liver Cancer (ITA.LI.CA) group: Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in Italy. Eur J Gastroenterol Hepatol 2012, 24(2):195-202.
• [18]Rosen CB, Heimbach JK, Gores GJ: Liver transplantation for cholangiocarcinoma. Transpl Int 2010, 23(7):692-697.
• [19]Becker NS, Rodriguez JA, Barshes NR, O’Mahony CA, Goss JA, Aloia TA: Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J Gastrointest Surg 2008, 12(1):117-122.
• [20]Friman S, Foss A, Isoniemi H, Olausson M, Höckerstedt K, Yamamoto S, Karlsen TH, Rizell M, Ericzon BG: Liver transplantation for cholangiocarcinoma: selection is essential for acceptable results. Scand J Gastroenterol 2011, 46(3):370-375.
• [21]Kaiser GM, Sotiropoulos GC, Jauch KW, Löhe F, Hirner A, Kalff JC, Königsrainer A, Steurer W, Senninger N, Brockmann JG, Schlitt HJ, Zülke C, Büchler MW, Schemmer P, Settmacher U, Hauss J, Lippert H, Hopt UT, Otto G, Heiss MM, Bechstein WO, Timm S, Klar E, Hölscher AH, Rogiers X, Stangl M, Hohenberger W, Müller V, Molmenti EP, Fouzas I, et al.: Liver transplantation for hilar cholangiocarcinoma: a German survey. Transplant Proc 2008, 40(9):3191-3193.
• [22]Rea DJ, Rosen CB, Nagorney DM, Heimbach JK, Gores GJ: Transplantation for cholangiocarcinoma: when and for whom? Surg Oncol Clin N Am 2009, 18(2):325-337.
• [23]Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B Jr, McCashland T, Sorrell M, Tempero M, Langnas A: Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2002, 2(8):774-779.
• [24]Pascher A, Jonas S, Neuhaus P: Intrahepatic cholangiocarcinoma: indication for transplantation. J Hepatobiliary Pancreat Surg 2003, 10(4):282-287.
• [25]Fu BS, Zhang T, Li H, Yi SH, Wang GS, Xu C, Yang Y, Cai CJ, Lu MQ, Chen GH: The role of liver transplantation for intrahepatic cholangiocarcinoma: a single-center experience. Eur Surg Res 2011, 47(4):218-221.
• [26]Gulec SA, Pennington K, Hall M, Fong Y: Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment: a novel approach to improving the safety of major hepatic resections. World J Surg Oncol 2009, 7:6.
• [27]Wang SC, Bester L, Burnes JP, Clouston JE, Hugh TJ, Little AF, Padbury RT, Price D: Clinical care and technical recommendations for 90 yttrium microsphere treatment of liver cancer. J Med Imaging Radiat Oncol 2010, 54(3):178-187.
• [28]Ahmadzadehfar H, Biersack HJ, Ezziddin S: Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med 2010, 40(2):105-121.
• [29]Prompers L, Bucerius J, Brans B, Temur Y, Berger L, Mottaghy FM: Selective internal radiation therapy (SIRT) in primary or secondary liver cancer. Methods 2011, 55(3):253-257.
• [30]Whitney R, Tatum C, Hahl M, Ellis S, Scoggins CR, McMasters K, Martin RC: Safety of hepatic resection in metastatic disease to the liver after yttrium-90 therapy. J Surg Res 2011, 166(2):236-240.
• [31]Geissler EK, Schlitt HJ, Thomas G: mTOR, cancer and transplantation. Am J Transplant 2008, 8(11):2212-2218.
• [32]Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002, 8(2):128-135.
• [33]Koehl GE, Andrassy J, Guba M, Richter S, Kroemer A, Scherer MN, Steinbauer M, Graeb C, Schlitt HJ, Jauch KW, Geissler EK: Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004, 77(9):1319-1326.
• [34]Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M: Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002, 73(10):1565-1572.
• [35]Willems MC, van der Vliet JA, de Man BM, van der Laak JA, Lomme RM, Hendriks T: Persistent effects of everolimus on strength of experimental wounds in intestine and fascia. Wound Repair Regen 2010, 18(1):98-104.
• [36]Kahn J, Müller H, Iberer F, Kniepeiss D, Duller D, Rehak P, Tscheliessnigg K: Incisional hernia following liver transplantation: incidence and predisposing factors. Clin Transplant 2007, 21(3):423-426.
• [37]Vardanian AJ, Farmer DG, Ghobrial RM, Busuttil RW, Hiatt JR: Incisional hernia after liver transplantation. J Am Coll Surg 2006, 203(4):421-425.
• [38]Brewer MB, Rada EM, Milburn ML, Goldberg NH, Singh DP, Cooper M, Silverman RP: Human acellular dermal matrix for ventral hernia repair reduces morbidity in transplant patients. Hernia 2011, 15(2):141-145.
• [39]Piardi T, Audet M, Panaro F, Gheza F, Cag M, Portolani N, Cinqualbre J, Wolf P: Incisional hernia repair after liver transplantation: role of the mesh. Transplant Proc 2010, 42(4):1244-1247.
• [40]Rosen MJ: Biologic mesh for abdominal wall reconstruction: a critical appraisal. Am Surg 2010, 76(1):1-6.